Bolt Biotherapeutics, Inc. (BOLT): restructuring charge — Bolt Biotherapeutics cuts workforce 50% and delays BDC-4182 data to Q3 2026

Bolt Biotherapeutics, Inc.

Workforce reduced by ~50% (approx. 20 employees); pre-tax charges $1.5-2.0M in Q4 2025.
Phase 1 study of BDC-4182 (claudin 18.2 ISAC) showing strong immune response; protocol modified for step-up dosing.
Initial clinical data for BDC-4182 now expected in Q3 2026, later than previously anticipated.
Cash runway extended into 2027 via restructuring and workforce reduction.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Bolt Biotherapeutics, Inc. announced a restructuring with charges of between approximately $1.5 million to $2.0 million affecting the Company (approximately 20 employees, or approximately 50% of the Company’s workforce).

Type: restructuring
Charge: between approximately $1.5 million to $2.0 million
Affected area: the Company
Headcount: approximately 20 employees, or approximately 50% of the Company’s workforce

Exact text from the filing

On October 1, 2025, Bolt Biotherapeutics, Inc., a Delaware corporation (the “Company”), implemented a restructuring plan pursuant to which it will reduce overall operating expenses to preserve cash. The restructuring plan includes a reduction of the Company’s current workforce by approximately 20 employees, or approximately 50% of the Company’s workforce. The Company estimates that it will incur aggregate pre-tax charges between approximately $1.5 million to $2.0 million in connection with the reduction-in-force, primarily consisting of severance payments, employee benefits, and related costs.

View on SEC.gov

Browse all restructurings & charges →

Bolt Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-228293

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.